Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis

Johannessen, Jane Krogh; Christiansen, I; Schmidt, Dorte Remmer; Petersen, Eskild; Hansen, Steen Honoré

doi:10.1016/j.jpba.2004.09.001

Cited by 24 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous HPLC-based techniques for measuring pyrimethamine and sulfadiazine plasma levels require 400 ll of whole blood, which is difficult to collect from infants except by venous puncture [1,25], and a new method for the simultaneous determination of pyrimethamine, sulfadiazine and its metabolite, N-acetylsulfadiazine, using only 25 ll of whole blood, was introduced in this study [12].…”

Section: Discussionmentioning

confidence: 99%

“…The children were recruited consecutively to this part of the study at the end of the study period. A simple sample preparation, based on protein precipitation and analysis, was performed on 25 ll plasma, using high performance liquid chromatography (HPLC) with ultraviolet (UV) and mass spectrometric (MS) detection [12]. Between seven and 11 samples were available from each child for calculation of the plasma concentrations.…”

Section: Plasma Levels Of Pyrimethamine and Sulfadiazinementioning

confidence: 99%

“…Pyrimethamine was found to give a linear response using MS detection in the range 0.02-5 lg/ml. Sulfadiazine and its metabolite, N-acetyl-sulfadiazine, were analysed by UV detection at 269 nm in the concentration ranges 0.2-200 lg/ml for sulfadiazine and 0.2-50 lg/ml for N-acetyl-sulfadiazine [12]. The parents were asked to record information on dosage, time of medication and sample taking, and not to give medication to the child on the morning of blood sampling.…”

Section: Plasma Levels Of Pyrimethamine and Sulfadiazinementioning

confidence: 99%

See 2 more Smart Citations

Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine

Schmidt

Høgh

Andersen³

et al. 2005

Eur J Pediatr

Self Cite

View full text Add to dashboard Cite

The aim was to study the tolerability and plasma concentrations of pyrimethamine and sulfadiazine in children treated for congenital toxoplasmosis. Infants were diagnosed through the Danish Toxoplasma Neonatal Screening Programme, based on detection of toxoplasma-specific IgM- and/or IgA-antibodies on 3 mm blood spots collected from phenylketonuria [PKU cards (Guthrie cards)]. Toxoplasma-infected children received 3 months' continuous treatment with 50-100 mg/kg per day sulfadiazine in two separate administrations and 1 mg/kg per day pyrimethamine after a 1-day loading dose of 2 mg/kg, and folinic acid 7.5 mg was administered twice weekly. Blood cell counts and body weight were recorded during follow-up. The plasma concentrations of pyrimethamine and sulfadiazine were analysed in a subgroup of seven children, using high performance liquid chromatography with ultraviolet and mass spectrometric detection. Of 48 infants, 41 completed the treatment without change in schedule. Six infants had neutrophil counts below 0.5x10(9)/l, and one infant had an elevated bilirubin value. Twenty-nine children were tested by a series of neutrophil counts during treatment. The neutrophil count was

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Plasma Levels Of Pyrimethamine and Sulfadiazinementioning

confidence: 99%

Section: Plasma Levels Of Pyrimethamine and Sulfadiazinementioning

confidence: 99%

See 1 more Smart Citation

Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine

Schmidt

Høgh

Andersen³

et al. 2005

Eur J Pediatr

Self Cite

View full text Add to dashboard Cite

show abstract

“…Complete blood cell, platelet and differential counts were performed weekly. A follow-up schedule was recommended, including observation of retinal changes and general development until 12 years of age (Schmidt et al 2006a;Nielsen et al 2005;Johannessen et al 2005).…”

Section: The National Neonatal Screening Programme For Ct In Denmarkmentioning

confidence: 99%

Congenital toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007

Röser

Nielsen

Petersen

et al. 2010

J of Inher Metab Disea

Self Cite

View full text Add to dashboard Cite

Screening was terminated August 2007, after it became apparent that no benefit of treatment could be shown. CT was evaluated using a Danish adaptation of the Uniform Screening Panel (ACMG), showing CT as an unlikely candidate for screening today. Whereas results might be comparable with other low-endemic countries with similar strains of T. gondii, neonatal screening and treatment might offer different results in regions with either high prevalence or different strains of T. gondii.

show abstract

“…Among them are reversed phase high performance liquid chromatography coupled with on-line atmospheric pressure chemical ionization mass spectrometry (HPLC/APCI-MS), 4 capillary zone electrophoresis, 5 18 and FIA system with amperometric detection. 19 However, most of them either require complicated and ex-pensive instruments, 4,[8][9][10][11]15,16 or are time consuming, 4,6,[12][13][14] or have high detection limit. 5,7,8,14,15,18 Therefore, the need for a sensitive, simple and reliable method for the determination of sulfadiazine is well recognized.…”

Section: Introductionmentioning

confidence: 99%

Indirect Determination of Sulfadiazine by Cloud Point Extraction/Flow Injection‐Flame Atomic Absorption (CPE/FI‐FAAS) Spectrometry

Dadfarnia

Hajishabani

Rad

2011

J Chinese Chemical Soc

View full text Add to dashboard Cite

An indirect simple and rapid cloud point extraction is proposed for separation and preconcentration of sulfadiazine and its determination by flow injection-flame atomic absorption spectroscopy (FI-FAAS). The sulfadiazine from 35 mL of solution was readily converted to silver sulfadiazine upon addition of silver nitrate (9.7 × 10 -5 mol/L). Then, Triton X-114 a non ionic surfactant was added and the solution was heated to 60°C. At this stage, two separate phases was formed and silver sulfadiazine enters the surfactant rich phase of non-ionic micelles of Triton X-114. The surfactant-rich phase (~50 µL) was then separated and diluted to 300 µL with acidic methanol. The concentration of silver in the surfactant-rich phase which is proportional to the concentration of sulfadiazine in sample solution was determined by FI-FAAS. The parameters affecting extraction and separation were optimized. Under the optimum conditions (i.e. pH 2-10, silver concentration (9.7 × 10 -5 mol/L), Triton X-114 (0.075% v/v) and temperature 60°C) a preconcentration factor of 117 and a relative standard deviation of 4.9% at 37 mg L -1 of sulfadiazine was obtained. The method was successfully applied to analysis of milk, urine and tablet samples and accuracy was determined by recovery experiments.

show abstract

Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis

Cited by 24 publications

References 19 publications

Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine

Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine

Congenital toxoplasmosis—a report on the Danish neonatal screening programme 1999–2007

Indirect Determination of Sulfadiazine by Cloud Point Extraction/Flow Injection‐Flame Atomic Absorption (CPE/FI‐FAAS) Spectrometry

Contact Info

Product

Resources

About